Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma

The primary objective of this study is to answer the question "Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects"?

Study Overview

• Status: Completed
• Conditions: Hepatocellular Carcinoma
• Intervention / Treatment: Biological: COMBIG-DC (ilixadencel)

Detailed Description

Patients diagnosed with hepatocellular carcinoma will get COMBIG-DC vaccinations at three occasions with 2-3 weeks and 3-5 weeks between vaccination 2 and 3 respectively. Adverse events will be registered until 6 months after last vaccination, as well as changes in vital signs (heart rate, blood pressure and body temperature) and lab parameters. Immunologic response will be evaluated by measuring immunologic markers in blood. The size of the tumor/tumors will be evaluated after 3 and 6 months and thereafter every three months until tumor progression.

For patients included after approval of Amendment 3 (2015-12-10), COMBIG-DC will be given as add on to standard treatment; sorafenib or Transarterial Chemoembolization (TACE).

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 1

Contacts and Locations

Study Locations

• Sweden
  • Gothenburg, Sweden, SE-413 45
    • Dept. of Transplantation and Liver Surgery, Sahlgrenska University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Be informed of the nature of the study and have provided written informed consent
• At least 18 years of age.
• Diagnosis of hepatocellular carcinoma according to EASL criteria or pathology.
• Radiologically measurable liver tumor(s), i.e. at least 20 mm in longest uni-dimensional diameter as measured by CT/MRI
• Not eligible for curatively aiming treatment or TACE. Tumor stage B or C according to BCLC.

• For patients included according to Amendment 3: tumour stage A, B or C according to BCLC and

  1. eligible for sorafenib treatment or having ongoing sorafenib treatment for not more than 4 weeks ant the time for inclusion or
  2. eligible for TACE or having received not more than 1 previous TACE treatment.

Exclusion Criteria:

• Performance status > ECOG 2
• Liver function according to Child-Pugh >7 points.
• Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxia or other serious reaction).
• Known major reaction/adverse event in connection with previous transfusions of blood products
• Active autoimmune disease requiring treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.
• Tested positive for HIV
• Active disease (HBV and HCV) requiring antiviral treatment
• Ongoing infection that requires treatment with antibiotics or antiviral medication
• Treatment with immunosuppressive treatments like corticosteroids (Immunosuppression (within 28 days) prior to the first injection of COMBIG-DC. Inhaled, intranasal and local steroids accepted), or mTor inhibitors within 28 days before first vaccination.
• Patients with prior history of malignancy other than HCC, within the preceding 3 years OR with relaps after complete response, except for 5 years follow-up of adequately treated in situ carcinoma without recurrences or non-melanoma skin cancer.

• Inadequate laboratory parameters, i.e.:

  1. P-Prothrombincomplex (PK) >1.4,
  2. Platelet count <50 75 x109/L
  3. Leukocyte count <3.0 x 109/L
  4. P-APT time outside normal limit
• Previous organ transplantation
• Women of Childbearing Potential (WOCBP) refusing to use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.
• Pregnant or lactating women
• Life expectancy less than 3 months.
• Concomitant anti-tumor treatment (within 28 days) prior to the first injection of COMBIG-DC, except for sorafenib or TACE for patients included according to Amendment 3.
• For patients included according to Amendment 3: Previous systemic anti-cancer treatment.
• Investigational treatment (within 28 days) prior to the first injection of COMBIG-DC.
• Known blood dyscrasia (bleeding complication).
• Known malignancy in CNS
• Any reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: COMBIG-DC; COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection	Biological: COMBIG-DC (ilixadencel); Allogenic dendrite-cell based therapeutic vaccine; Other Names: ilixadencel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Registration of adverse events as a measure of safety and tolerability	Changes in vital signs from baseline (heart rate, blood pressure, body temperature); Changes in lab parameters from baseline; Short term worsening in ECOG and/or Child Pugh and/or MELD score; Local procedural injuries, assessed by MRI or ultrasound	Up to 6 months after last patient's last vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate systemic inflammatory response	Potential systemic release of relevant cytokines, chemokines and other inflammatory parameters in blood;IL-1R, IL-2,IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, G-CSF. GM-CSF, IFN-gamma, MCP-1, MIP-1 beta and TNF-alpha.	Until 3 months after last vaccination
To evaluate tumor control	CT/MRI evaluation 3 and 6 months after first vaccination. Patients with stable disease or tumor response will continue tumor evaluation every 3rd month until progress or until last study patient has had his/her 6 month visit.; Measuring number of tumor specific T cells with flow cytometry after in vitro stimulation with different pools of HCC-associated tumor peptides (Alpha-feto protein (AFP), and hTERT); Measuring AFP (alpha-feto protein) levels in blood; Measuring the level of circulating tumor cell, identified as tested positive for MICA, EpCAM, CD133, CD34, CK18	Until 6 months after last patient's last vaccination
Long term changes in ECOG scores		3 and 6 months after last vaccination
Change in body weight		3 and 6 months after last vaccination
To evaluate systemic immunological response	Vaccine cell tracking; PBMCs will be stained with antibodies specific for one HLA class I or one HLA-class II antigen that is selectively expressed on donor vaccine cells.; vaccine-induced alloimmunization; screening of alloantibodies against HLA-A, B, C (MHC-class I) and HLA-DR, DQ, DP (MHC-class II) antigens; autoimmune events; screening of autoantibodies against autoantigens, including nuclear antigens (ANA, SSA, SSB, Sm, RNP, Scl-70, Centromeres and Jo-1) and liver parenchyma-associated autoantigens (liver-kidney microsomal antigens and mitochondrial antigens); complement activation; classical/alternative complement function, C3, C4, C3d, and Factor-B.; immune cell occurrence and activation state; CD3+ , CD3+4+ and CD3+8+ T cells, CD19+ B-cells CD3-16+56+ NK-cells, CD3-16+56+69+ NK cells, CD3+16+56+ NKT-cells, CD3+16+56+69+ NKT-cells and CD3+HLA-DR+ T cells.	Up to 3 months after last vaccination
Long term changes in Quality of Life scores		3 and 6 months after last vaccination
To evaluate immunological response	complement activation; classical/alternative complement function, C3, C4, C3d, and Factor-B.; immune cell occurrence and activation state; CD3+ , CD3+4+ and CD3+8+ T cells, CD19+ B-cells CD3-16+56+ NK-cells, CD3-16+56+69+ NK cells, CD3+16+56+ NKT-cells, CD3+16+56+69+ NKT-cells and CD3+HLA-DR+ T cells.	Up to 3 months after last vaccination
Changes in HBV, HCV virus titers	Changes in HBV, HCV virus titers vs baseline, for patients that are tested positive at screening	Day 8 after each injection and at the 3 and 6 months visit
To study time to progress (TTP)	TTP measured as time from first dose of COMBIG-DC until radiologically proven progress according to mRECIST.	Measured every 3 months until progression
To study overall survival (OS)	OS measured as survival time from first dose of COMBIG-DC until end of study or death (whichever comes first)	Up to 6 months after last patient's last vaccination

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI	An optional addition to the assessment of local procedural injuries (primary outcome).	1 month after each vaccination

Collaborators and Investigators

• Sponsor: Mendus
• Collaborators: Uppsala University
• Investigators: Principal Investigator: Magnus Rizell, MD, PhD, Sahlgrenska University Hospital, Sweden

Publications and helpful links

General Publications

• Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019 Jan 21;9:19. doi: 10.3389/fonc.2019.00019. eCollection 2019.

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (ACTUAL): June 28, 2017
• Study Completion (ACTUAL): June 28, 2017

Study Registration Dates

• First Submitted: October 21, 2013
• First Submitted That Met QC Criteria: October 25, 2013
• First Posted (ESTIMATE): November 1, 2013

Study Record Updates

• Last Update Posted (ACTUAL): September 29, 2017
• Last Update Submitted That Met QC Criteria: September 27, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: IM-102; 2013-001787-31 (EUDRACT_NUMBER)